MicroRNA Expression Profiling of Sputum for the Detection of Early and Locally Advanced Non-Small-Cell Lung Cancer: A Prospective Case–Control Study

Razzak, Rene; Bédard, Éric; Kim, J.O.; Gazala, Sayf; Guo, Linghong; Ghosh, Sunita; Joy, Anil A.; Nijjar, Tirath; Wong, Eric T.; Roa, Wilson

doi:10.3747/co.23.2830

Cited by 35 publications

(33 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this period, 12 studies were excluded because they are reviews or meta-analyses (n=5), insu ciency information (n=3), detecting miRNA methylation (n=2) or data overlapping (n=2). As a result, 16 articles 11,13,[19][20][21][22][23][24][25][26][27][28][29][30][31][32] were eligible for nal meta-anlaysis. Figure 1A showed the process of studies identi cation.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…These studies published from 2010 to 2018, and the sample size ranged from 30 to 315. Two studies conducted in Asian 24,27 , seven studies conducted in Caucasian 13,20,25,[28][29][30][31] and the remaining seven studies 11,19,[21][22][23]26,32 conducted in mixed population. Two studies 19,26 selected healthy population as controls, 11 studies 13,20-23,25,28-32 selected cancer-free subjects as controls, and the remaining three studies 11,24,27 applied benign pulmonary disease (BPD) as controls.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…We sorted the miRNAs reported by at least two studies that could serve as potential biomarkers. In upregulated miRNAs, 11 studies reported miR-210, 11,[20][21][22][23][25][26][27][28]31,32 eight studies reported miR-21 11,13,19,22,24,25,27,32 and six studies reported miR-31. 11,21-23, 32,37 miR-205, 11,22,26 miR-182, 11,19,22 miR-200b 11,19,22 and miR-155 11,24,26 had been reported by three studies.…”

Section: Potential Useful Sputum Mirnas Identi Ed From Literaturementioning

confidence: 99%

See 2 more Smart Citations

The Diagnostic Role of Sputum miRNA in Non-Small Cell Lung Cancer

Hu¹,

Zhao²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: Recent studies indicated sputum miRNAs may provide a promising approach for non-small cell lung cancer (NSCLC) diagnosis. But some results were still inconsistent. So, we performed meta-analysis to evaluate the diagnostic role of sputum miRNAs for the detection of NSCLC.Methods: Eligible studies that estimated the diagnostic accuracy of sputum miRNAs in NSCLC were searched in Pubmed, Embase and Web of Science and Chinese National Knowledge Infrastructure (CNKI). Data from the eligible studies were collected and pooled; sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratios, weighted symmetric summary ROC curve and the area under the curve (AUC) were calculated by bi-variate random effects model. The between-study heterogeneity was evaluated by Q test and I2 statistics.Results: 30 studies from 16 articles were included for analysis. The overall analysis yielded the sensitivity of 0.77 (95% CI: 0.73–0.81) and specificity of 0.87 (95% CI: 0.83–0.90), with an area under the SROC curve (AUC) of 0.89 (95% CI: 0.86–0.91). Subgroup analysis revealed the diagnostic accuracy in multiple miRNAs studies was higher than single miRNA (the sensitivity, specifcity and an AUC of multiple miRNAs were 0.76, 0.88 and 0.90; and for single miRNA, it was 0.74, 0.74, and 0.80). The diagnostic performance in early stage NSCLC was also very high (the sensitivity, specifcity and an AUC of stage I/II was 0.76, 0.88 and 0.91; and for stage I, it was 0.79, 0.85, and 0.87). We also found miR-210, miR-21, miR-31 and miR-126-3p might serve as potential biomarkers for lung cancer.Conclusion: Sputum miRNAs was useful noninvasive biomarkers for NSCLC diagnosis.

show abstract

Section: Eligible Studiesmentioning

confidence: 99%

Section: Eligible Studiesmentioning

confidence: 99%

Section: Potential Useful Sputum Mirnas Identi Ed From Literaturementioning

confidence: 99%

See 1 more Smart Citation

The Diagnostic Role of Sputum miRNA in Non-Small Cell Lung Cancer

Hu¹,

Zhao²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, we have shown that downregulations of miR‐486‐5p contribute to the development of NSCLC by regulating Pim‐1 and ARHGAP5 . We and others have also demonstrated that aberrant miRNA expressions detected in sputum biologically reflect those in primary lung cancer . We have recently developed a panel of two sputum miRNA (miR‐31‐5p and miR‐210‐3p) biomarkers for NSCLC with 65% sensitivity and 89% specificity .…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7][8] We and others have also demonstrated that aberrant miRNA expressions detected in sputum biologically reflect those in primary lung cancer. [9][10][11][12][13][14][15] We have recently developed a panel of two sputum miRNA (miR-31-5p and miR-210-3p) biomarkers for NSCLC with 65% sensitivity and 89% specificity. 16 Furthermore, efforts have been made to develop cell-free (eg, plasma) biomarkers by detecting the circulating molecules directly released from lung tumors.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)

et al. 2020

View full text Add to dashboard Cite

Background The development of biomarkers for the early detection of non‐small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC. Methods Using reverse transcription PCR, we determined expressions of two miRNAs (miRs‐31‐5p and 210‐3p) in sputum and three miRNAs (miRs‐21‐5p, 210‐3p, and 486‐5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer‐free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer‐free smokers. Results The panels of two sputum miRNAs and three plasma miRNAs had 65.8–75.0% sensitivities and 83.3–87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs‐31‐5p and 210‐3p) and one plasma miRNA (miR‐21‐5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort. Conclusions Integrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. Key points Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone

show abstract

miRNA as biomarker in lung cancer

Lobera,

Varela,

Jimenez

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

Lung cancer has a high prevalence and mortality due to its late diagnosis and limited treatment, so it is essential to find biomarkers that allow a faster diagnosis and improve the survival of these patients. In this sense, biomarkers based on miRNAs have supposed a considerable advance. miRNAs, which are small RNA sequences, can regulate gene expression, so they play an essential role not only as a diagnostic biomarker but also as a therapeutic and prognostic one. Also, miRNA biomarkers can be obtained from liquid biopsies, which are less intrusive than lung biopsies, and have better accessibility, safety and repeatability, which allows using those biomarkers both for diagnosis and monitoring of patients. In this review, we highlight the importance of miRNAs and collect the existing evidence of their relationship with lung cancer.

show abstract

MicroRNA Expression Profiling of Sputum for the Detection of Early and Locally Advanced Non-Small-Cell Lung Cancer: A Prospective Case–Control Study

Abstract: Background Non-small-cell lung cancer (nsclc) is associated with very poor overall survival because 70% of

Cited by 35 publications

References 41 publications

The Diagnostic Role of Sputum miRNA in Non-Small Cell Lung Cancer

The Diagnostic Role of Sputum miRNA in Non-Small Cell Lung Cancer

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)

miRNA as biomarker in lung cancer

Contact Info

Product

Resources

About